HemaCare Corporation, a rising young company that provides blood products and services in the healthcare industry, announced today second quarter 2009 results which include a 5% increase in revenue compared to the same quarter in 2008.

HemaCare, which is licensed by the FDA and accredited by the AABB, showed income from continuing operations of $369,000 for the second quarter which dwarfed the $165,000 for the same quarter in 2008. This represents an increase of 124% or $0.04 per share.

When asked about the impact of these numbers, HemaCare CEO John Doumitt responded, “We are pleased to report record revenues and improved profitability in the second quarter. This is the seventh consecutive quarter of profits from continuing operations, and we continue to see benefits from our operational improvement and sales initiatives. We remain committed to growing sales and margins in an increasingly competitive environment by delivering exceptional value to customers.”

The main focus of HemaCare is the customized delivery of human blood-related products and services. This unique mandate has started to catch the eye of investors and the company has bucked market trends by producing profits for seven consecutive quarters.

While the atmosphere on Wall Street has been one of morose depression, there are signs that things have started to turnaround. A company such as HemaCare has been providing profits for its investors despite such conditions. HemaCare may be a hidden jewel one can find over-the-counter that may end up being a major player on Wall Street in the near future.